5dd0 › Citations

Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages.

Zhang R, Verkoczy L, Wiehe K, Munir Alam S, Nicely NI, Santra S, Bradley T, Pemble CW, Zhang J, Gao F, Montefiori DC, Bouton-Verville H, Kelsoe G, Larimore K, Greenberg PD, Parks R, Foulger A, Peel JN, Luo K, Lu X, Trama AM, Vandergrift N, Tomaras GD, Kepler TB, Moody MA, Liao HX, Haynes BF
Sci Transl Med 8 336ra62 (2016)
Related entries: 5dd1, 5dd3, 5dd5, 5dd6

Cited: 59 times
EuropePMC logo PMID: 27122615

Abstract

Development of an HIV vaccine is a global priority. A major roadblock to a vaccine is an inability to induce protective broadly neutralizing antibodies (bnAbs). HIV gp41 bnAbs have characteristics that predispose them to be controlled by tolerance. We used gp41 2F5 bnAb germline knock-in mice and macaques vaccinated with immunogens reactive with germline precursors to activate neutralizing antibodies. In germline knock-in mice, bnAb precursors were deleted, with remaining anergic B cells capable of being activated by germline-binding immunogens to make gp41-reactive immunoglobulin M (IgM). Immunized macaques made B cell clonal lineages targeted to the 2F5 bnAb epitope, but 2F5-like antibodies were either deleted or did not attain sufficient affinity for gp41-lipid complexes to achieve the neutralization potency of 2F5. Structural analysis of members of a vaccine-induced antibody lineage revealed that heavy chain complementarity-determining region 3 (HCDR3) hydrophobicity was important for neutralization. Thus, gp41 bnAbs are controlled by immune tolerance, requiring vaccination strategies to transiently circumvent tolerance controls.

Articles - 5dd0 mentioned but not cited (3)

  1. Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages. Zhang R, Verkoczy L, Wiehe K, Munir Alam S, Nicely NI, Santra S, Bradley T, Pemble CW, Zhang J, Gao F, Montefiori DC, Bouton-Verville H, Kelsoe G, Larimore K, Greenberg PD, Parks R, Foulger A, Peel JN, Luo K, Lu X, Trama AM, Vandergrift N, Tomaras GD, Kepler TB, Moody MA, Liao HX, Haynes BF. Sci Transl Med 8 336ra62 (2016)
  2. Structure of the membrane proximal external region of HIV-1 envelope glycoprotein. Fu Q, Shaik MM, Cai Y, Ghantous F, Piai A, Peng H, Rits-Volloch S, Liu Z, Harrison SC, Seaman MS, Chen B, Chou JJ. Proc Natl Acad Sci U S A 115 E8892-E8899 (2018)
  3. Structural Features of Antibody-Peptide Recognition. Lee JH, Yin R, Ofek G, Pierce BG. Front Immunol 13 910367 (2022)


Reviews citing this publication (20)

  1. Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. Bonsignori M, Liao HX, Gao F, Williams WB, Alam SM, Montefiori DC, Haynes BF. Immunol Rev 275 145-160 (2017)
  2. Progress toward active or passive HIV-1 vaccination. Escolano A, Dosenovic P, Nussenzweig MC. J Exp Med 214 3-16 (2017)
  3. Germline-targeting immunogens. Stamatatos L, Pancera M, McGuire AT. Immunol Rev 275 203-216 (2017)
  4. Host controls of HIV broadly neutralizing antibody development. Kelsoe G, Haynes BF. Immunol Rev 275 79-88 (2017)
  5. The expanding array of HIV broadly neutralizing antibodies. McCoy LE. Retrovirology 15 70 (2018)
  6. Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target. Molinos-Albert LM, Clotet B, Blanco J, Carrillo J. Front Immunol 8 1154 (2017)
  7. HIV vaccinology: 2021 update. Lee JH, Crotty S. Semin Immunol 51 101470 (2021)
  8. Strategies for inducing effective neutralizing antibody responses against HIV-1. Del Moral-Sánchez I, Sliepen K. Expert Rev Vaccines 18 1127-1143 (2019)
  9. Approaches to the induction of HIV broadly neutralizing antibodies. Moore PL, Williamson C. Curr Opin HIV AIDS 11 569-575 (2016)
  10. Neutralizing Antibodies Targeting HIV-1 gp41. Caillat C, Guilligay D, Sulbaran G, Weissenhorn W. Viruses 12 E1210 (2020)
  11. Control of autoreactive B cells by IgM and IgD B cell receptors: maintaining a fine balance. Noviski M, Zikherman J. Curr Opin Immunol 55 67-74 (2018)
  12. Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem. Verkoczy L. Adv Immunol 134 235-352 (2017)
  13. Immunological tolerance as a barrier to protective HIV humoral immunity. Schroeder KM, Agazio A, Torres RM. Curr Opin Immunol 47 26-34 (2017)
  14. Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies. Williams WB, Wiehe K, Saunders KO, Haynes BF. J Int AIDS Soc 24 Suppl 7 e25831 (2021)
  15. What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Breaking through Immunity's Glass Ceiling. Kelsoe G, Haynes BF. Cold Spring Harb Perspect Biol 10 a029397 (2018)
  16. Minding the gap: The impact of B-cell tolerance on the microbial antibody repertoire. Finney J, Watanabe A, Kelsoe G, Kuraoka M. Immunol Rev 292 24-36 (2019)
  17. Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination. Mu Z, Haynes BF, Cain DW. Curr Opin Virol 51 172-178 (2021)
  18. Hepatitis C Virus Epitope Immunodominance and B Cell Repertoire Diversity. Brasher NA, Adhikari A, Lloyd AR, Tedla N, Bull RA. Viruses 13 983 (2021)
  19. B Cells Carrying Antigen Receptors Against Microbes as Tools for Vaccine Discovery and Design. Bhullar D, Nemazee D. Curr Top Microbiol Immunol 428 165-180 (2020)
  20. B cells in the balance: Offsetting self-reactivity avoidance with protection against foreign. Young C, Lau AWY, Burnett DL. Front Immunol 13 951385 (2022)

Articles citing this publication (36)

  1. Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. Saunders KO, Wiehe K, Tian M, Acharya P, Bradley T, Alam SM, Go EP, Scearce R, Sutherland L, Henderson R, Hsu AL, Borgnia MJ, Chen H, Lu X, Wu NR, Watts B, Jiang C, Easterhoff D, Cheng HL, McGovern K, Waddicor P, Chapdelaine-Williams A, Eaton A, Zhang J, Rountree W, Verkoczy L, Tomai M, Lewis MG, Desaire HR, Edwards RJ, Cain DW, Bonsignori M, Montefiori D, Alt FW, Haynes BF. Science 366 eaay7199 (2019)
  2. Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. Williams LD, Ofek G, Schätzle S, McDaniel JR, Lu X, Nicely NI, Wu L, Lougheed CS, Bradley T, Louder MK, McKee K, Bailer RT, O'Dell S, Georgiev IS, Seaman MS, Parks RJ, Marshall DJ, Anasti K, Yang G, Nie X, Tumba NL, Wiehe K, Wagh K, Korber B, Kepler TB, Munir Alam S, Morris L, Kamanga G, Cohen MS, Bonsignori M, Xia SM, Montefiori DC, Kelsoe G, Gao F, Mascola JR, Moody MA, Saunders KO, Liao HX, Tomaras GD, Georgiou G, Haynes BF. Sci Immunol 2 eaal2200 (2017)
  3. Anti-HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity. Dosenovic P, Kara EE, Pettersson AK, McGuire AT, Gray M, Hartweger H, Thientosapol ES, Stamatatos L, Nussenzweig MC. Proc Natl Acad Sci U S A 115 4743-4748 (2018)
  4. A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation. Violari A, Cotton MF, Kuhn L, Schramm DB, Paximadis M, Loubser S, Shalekoff S, Da Costa Dias B, Otwombe K, Liberty A, McIntyre J, Babiker A, Gibb D, Tiemessen CT. Nat Commun 10 412 (2019)
  5. Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development. Wiehe K, Bradley T, Meyerhoff RR, Hart C, Williams WB, Easterhoff D, Faison WJ, Kepler TB, Saunders KO, Alam SM, Bonsignori M, Haynes BF. Cell Host Microbe 23 759-765.e6 (2018)
  6. Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. Williams WB, Zhang J, Jiang C, Nicely NI, Fera D, Luo K, Moody MA, Liao HX, Alam SM, Kepler TB, Ramesh A, Wiehe K, Holland JA, Bradley T, Vandergrift N, Saunders KO, Parks R, Foulger A, Xia SM, Bonsignori M, Montefiori DC, Louder M, Eaton A, Santra S, Scearce R, Sutherland L, Newman A, Bouton-Verville H, Bowman C, Bomze H, Gao F, Marshall DJ, Whitesides JF, Nie X, Kelsoe G, Reed SG, Fox CB, Clary K, Koutsoukos M, Franco D, Mascola JR, Harrison SC, Haynes BF, Verkoczy L. Nat Commun 8 1732 (2017)
  7. Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. Saunders KO, Nicely NI, Wiehe K, Bonsignori M, Meyerhoff RR, Parks R, Walkowicz WE, Aussedat B, Wu NR, Cai F, Vohra Y, Park PK, Eaton A, Go EP, Sutherland LL, Scearce RM, Barouch DH, Zhang R, Von Holle T, Overman RG, Anasti K, Sanders RW, Moody MA, Kepler TB, Korber B, Desaire H, Santra S, Letvin NL, Nabel GJ, Montefiori DC, Tomaras GD, Liao HX, Alam SM, Danishefsky SJ, Haynes BF. Cell Rep 18 2175-2188 (2017)
  8. Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza Viruses. Guthmiller JJ, Lan LY, Fernández-Quintero ML, Han J, Utset HA, Bitar DJ, Hamel NJ, Stovicek O, Li L, Tepora M, Henry C, Neu KE, Dugan HL, Borowska MT, Chen YQ, Liu STH, Stamper CT, Zheng NY, Huang M, Palm AE, García-Sastre A, Nachbagauer R, Palese P, Coughlan L, Krammer F, Ward AB, Liedl KR, Wilson PC. Immunity 53 1230-1244.e5 (2020)
  9. Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. Williams WB, Meyerhoff RR, Edwards RJ, Li H, Manne K, Nicely NI, Henderson R, Zhou Y, Janowska K, Mansouri K, Gobeil S, Evangelous T, Hora B, Berry M, Abuahmad AY, Sprenz J, Deyton M, Stalls V, Kopp M, Hsu AL, Borgnia MJ, Stewart-Jones GBE, Lee MS, Bronkema N, Moody MA, Wiehe K, Bradley T, Alam SM, Parks RJ, Foulger A, Oguin T, Sempowski GD, Bonsignori M, LaBranche CC, Montefiori DC, Seaman M, Santra S, Perfect J, Francica JR, Lynn GM, Aussedat B, Walkowicz WE, Laga R, Kelsoe G, Saunders KO, Fera D, Kwong PD, Seder RA, Bartesaghi A, Shaw GM, Acharya P, Haynes BF. Cell 184 2955-2972.e25 (2021)
  10. Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. Roark RS, Li H, Williams WB, Chug H, Mason RD, Gorman J, Wang S, Lee FH, Rando J, Bonsignori M, Hwang KK, Saunders KO, Wiehe K, Moody MA, Hraber PT, Wagh K, Giorgi EE, Russell RM, Bibollet-Ruche F, Liu W, Connell J, Smith AG, DeVoto J, Murphy AI, Smith J, Ding W, Zhao C, Chohan N, Okumura M, Rosario C, Ding Y, Lindemuth E, Bauer AM, Bar KJ, Ambrozak D, Chao CW, Chuang GY, Geng H, Lin BC, Louder MK, Nguyen R, Zhang B, Lewis MG, Raymond DD, Doria-Rose NA, Schramm CA, Douek DC, Roederer M, Kepler TB, Kelsoe G, Mascola JR, Kwong PD, Korber BT, Harrison SC, Haynes BF, Hahn BH, Shaw GM. Science 371 eabd2638 (2021)
  11. Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. Bradley T, Trama A, Tumba N, Gray E, Lu X, Madani N, Jahanbakhsh F, Eaton A, Xia SM, Parks R, Lloyd KE, Sutherland LL, Scearce RM, Bowman CM, Barnett S, Abdool-Karim SS, Boyd SD, Melillo B, Smith AB, Sodroski J, Kepler TB, Alam SM, Gao F, Bonsignori M, Liao HX, Moody MA, Montefiori D, Santra S, Morris L, Haynes BF. EBioMedicine 12 196-207 (2016)
  12. Breaching peripheral tolerance promotes the production of HIV-1-neutralizing antibodies. Schroeder KMS, Agazio A, Strauch PJ, Jones ST, Thompson SB, Harper MS, Pelanda R, Santiago ML, Torres RM. J Exp Med 214 2283-2302 (2017)
  13. Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity. Prigent J, Jarossay A, Planchais C, Eden C, Dufloo J, Kök A, Lorin V, Vratskikh O, Couderc T, Bruel T, Schwartz O, Seaman MS, Ohlenschläger O, Dimitrov JD, Mouquet H. Cell Rep 23 2568-2581 (2018)
  14. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. LaBranche CC, McGuire AT, Gray MD, Behrens S, Kwong PDK, Chen X, Zhou T, Sattentau QJ, Peacock J, Eaton A, Greene K, Gao H, Tang H, Perez LG, Chen X, Saunders KO, Kwong PD, Mascola JR, Haynes BF, Stamatatos L, Montefiori DC. PLoS Pathog 14 e1007431 (2018)
  15. Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. Kadelka C, Liechti T, Ebner H, Schanz M, Rusert P, Friedrich N, Stiegeler E, Braun DL, Huber M, Scherrer AU, Weber J, Uhr T, Kuster H, Misselwitz B, Cavassini M, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Kouyos RD, Günthard HF, Trkola A, Swiss HIV Cohort Study. J Exp Med 215 1589-1608 (2018)
  16. Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization. Han Q, Bradley T, Williams WB, Cain DW, Montefiori DC, Saunders KO, Parks RJ, Edwards RW, Ferrari G, Mueller O, Shen X, Wiehe KJ, Reed S, Fox CB, Rountree W, Vandergrift NA, Wang Y, Sutherland LL, Santra S, Moody MA, Permar SR, Tomaras GD, Lewis MG, Van Rompay KKA, Haynes BF. Cell Rep 30 1553-1569.e6 (2020)
  17. Optimal Development of Mature B Cells Requires Recognition of Endogenous Antigens. Noviski M, Tan C, Huizar J, Vykunta V, Mueller JL, Zikherman J. J Immunol 203 418-428 (2019)
  18. Widespread B cell perturbations in HIV-1 infection afflict naive and marginal zone B cells. Liechti T, Kadelka C, Braun DL, Kuster H, Böni J, Robbiani M, Günthard HF, Trkola A. J Exp Med 216 2071-2090 (2019)
  19. Clonal anergy of CD117+chB6+ B cell progenitors induced by avian leukosis virus subgroup J is associated with immunological tolerance. He S, Zheng G, Zhou D, Li G, Zhu M, Du X, Zhou J, Cheng Z. Retrovirology 16 1 (2019)
  20. Human Immunodeficiency Virus Proteins Mimic Human T Cell Receptors Inducing Cross-Reactive Antibodies. Root-Bernstein R. Int J Mol Sci 18 E2091 (2017)
  21. Cross-Reactivity to Kynureninase Tolerizes B Cells That Express the HIV-1 Broadly Neutralizing Antibody 2F5. Finney J, Yang G, Kuraoka M, Song S, Nojima T, Verkoczy L, Kitamura D, Haynes BF, Kelsoe G. J Immunol 203 3268-3281 (2019)
  22. Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes. Bancroft T, DeBuysscher BL, Weidle C, Schwartz A, Wall A, Gray MD, Feng J, Steach HR, Fitzpatrick KS, Gewe MM, Skog PD, Doyle-Cooper C, Ota T, Strong RK, Nemazee D, Pancera M, Stamatatos L, McGuire AT, Taylor JJ. J Exp Med 216 2331-2347 (2019)
  23. Development of a Novel Assay to Assess the Avidity of Dengue Virus-Specific Antibodies Elicited in Response to a Tetravalent Dengue Vaccine. Tsuji I, Dominguez D, Egan MA, Dean HJ. J Infect Dis 225 1533-1544 (2022)
  24. Optimization of the EC26-2A4 Epitope in the gp41 Membrane Proximal External Region Targeted by Neutralizing Antibodies from an Elite Controller. Ringel O, Müller K, Koch J, Brill B, Wolf T, Stephan C, Vieillard V, Debré P, Dietrich U. AIDS Res Hum Retroviruses 34 365-374 (2018)
  25. Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant. Beltran-Pavez C, Ferreira CB, Merino-Mansilla A, Fabra-Garcia A, Casadella M, Noguera-Julian M, Paredes R, Olvera A, Haro I, Brander C, Garcia F, Gatell JM, Yuste E, Sanchez-Merino V. PLoS One 13 e0208345 (2018)
  26. mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. Mu Z, Wiehe K, Saunders KO, Henderson R, Cain DW, Parks R, Martik D, Mansouri K, Edwards RJ, Newman A, Lu X, Xia SM, Eaton A, Bonsignori M, Montefiori D, Han Q, Venkatayogi S, Evangelous T, Wang Y, Rountree W, Korber B, Wagh K, Tam Y, Barbosa C, Alam SM, Williams WB, Tian M, Alt FW, Pardi N, Weissman D, Haynes BF. Cell Rep 38 110514 (2022)
  27. Induction of broadly reactive influenza antibodies increases susceptibility to autoimmunity. Labombarde JG, Pillai MR, Wehenkel M, Lin CY, Keating R, Brown SA, Crawford JC, Brice DC, Castellaw AH, Mandarano AH, Guy CS, Mejia JR, Lewis CD, Chang TC, Oshansky CM, Wong SS, Webby RJ, Yan M, Li QZ, Marion TN, Thomas PG, McGargill MA. Cell Rep 38 110482 (2022)
  28. Stabilized HIV-1 envelope immunization induces neutralizing antibodies to the CD4bs and protects macaques against mucosal infection. Saunders KO, Edwards RJ, Tilahun K, Manne K, Lu X, Cain DW, Wiehe K, Williams WB, Mansouri K, Hernandez GE, Sutherland L, Scearce R, Parks R, Barr M, DeMarco T, Eater CM, Eaton A, Morton G, Mildenberg B, Wang Y, Rountree RW, Tomai MA, Fox CB, Moody MA, Alam SM, Santra S, Lewis MG, Denny TN, Shaw GM, Montefiori DC, Acharya P, Haynes BF. Sci Transl Med 14 eabo5598 (2022)
  29. Histone H2A-Reactive B Cells Are Functionally Anergic in Healthy Mice With Potential to Provide Humoral Protection Against HIV-1. Agazio A, Cimons J, Shotts KM, Guo K, Santiago ML, Pelanda R, Torres RM. Front Immunol 11 1565 (2020)
  30. B cells expressing IgM B cell receptors of HIV-1 neutralizing antibodies discriminate antigen affinities by sensing binding association rates. Hossain MA, Anasti K, Watts B, Cronin K, Derking R, Groschel B, Kane AP, Edwards RJ, Easterhoff D, Zhang J, Rountree W, Ortiz Y, Saunders K, Schief WR, Sanders RW, Verkoczy L, Reth M, Alam SM. Cell Rep 39 111021 (2022)
  31. Development of Neutralization Breadth against Diverse HIV-1 by Increasing Ab-Ag Interface on V2. Gao N, Gai Y, Meng L, Wang C, Wang W, Li X, Gu T, Louder MK, Doria-Rose NA, Wiehe K, Nazzari AF, Olia AS, Gorman J, Rawi R, Wu W, Smith C, Khant H, de Val N, Yu B, Luo J, Niu H, Tsybovsky Y, Liao H, Kepler TB, Kwong PD, Mascola JR, Qin C, Zhou T, Yu X, Gao F. Adv Sci (Weinh) 9 e2200063 (2022)
  32. Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120. Yu JS, Liao HX, Pritchett J, Bowman C, Vivian C, Parks R, Xia SM, Cooper M, Williams WB, Bonsignori M, Reed SG, Chen M, Vandergrift N, Rice CM, Haynes BF. J Virol Methods 249 85-93 (2017)
  33. Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions. Caniels TG, Medina-Ramírez M, Zhang J, Sarkar A, Kumar S, LaBranche A, Derking R, Allen JD, Snitselaar JL, Capella-Pujol J, Sánchez IDM, Yasmeen A, Diaz M, Aldon Y, Bijl TPL, Venkatayogi S, Martin Beem JS, Newman A, Jiang C, Lee WH, Pater M, Burger JA, van Breemen MJ, de Taeye SW, Rantalainen K, LaBranche C, Saunders KO, Montefiori D, Ozorowski G, Ward AB, Crispin M, Moore JP, Klasse PJ, Haynes BF, Wilson IA, Wiehe K, Verkoczy L, Sanders RW. Cell Rep Med 4 101003 (2023)
  34. Antiretroviral naive and treated patients: Discrepancies of B cell subsets during the natural course of human immunodeficiency virus type 1 infection. Tsachouridou O, Skoura L, Zebekakis P, Margariti A, Georgiou A, Bougiouklis D, Pilalas D, Galanos A, Daniilidis M, Metallidis S. World J Virol 5 155-160 (2016)
  35. HIV-1 prehairpin intermediate inhibitors show efficacy independent of neutralization tier. Bell BN, Bruun TUJ, Friedland N, Kim PS. Proc Natl Acad Sci U S A 120 e2215792120 (2023)
  36. Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development. Haynes BF, Wiehe K, Alam SM, Weissman D, Saunders KO. Curr Opin HIV AIDS 18 300-308 (2023)


Quick links